Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for ...
StockStory.org on MSN16h
Why Sarepta Therapeutics (SRPT) Shares Are Sliding TodayShares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...
Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...
Nvidia stock falls as CEO Jensen Huang delivers his keynote speech at the chip maker’s GTC AI conference, Intel shares extend ...
Investor's Business Daily on MSN12h
Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.Dystrophin helps keep muscles intact and functional.William Blair's Corwin noted two patients died following treatment with Novartis' Zolgensma, a treatment for spinal muscular atrophy."Overall, we ...
Jefferies expects stock price weakness Sarepta (SRPT) following news of a Duchenne muscular dystrophy patient death caused by acute liver failure. Although liver toxicity is a known side effect, ...
Regenxbio (NASDAQ:RGNX) and Solid Biosciences (NASDAQ:SLDB) witnessed contrasting fortunes on Tuesday after Sarepta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback